SCHEMBL2867832

SCHEMBL2867832

CC(C)(C)Oc1ccc(C[C@@H](N)C(=O)O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.68
SLC7A5 Q01650 4/20 0.57
PTGS1 P23219 3/20 0.56
ALPI P09923 1/20 0.56
PKM P14618 1/20 0.56
XIAP P98170 1/20 0.56
ITGB3 P05106 1/20 0.55
ITGA2B P08514 1/20 0.55
GRB2 P62993 1/20 0.53
ACACB O00763 1/20 0.52
TPH1 P17752 3/20 0.49
ALOX15 P16050 3/20 0.49
HIF1A Q16665 3/20 0.49
KDM4E B2RXH2 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
USP2 O75604 1/20 0.49
EGFR P00533 1/20 0.49
LCK P06239 1/20 0.49
FYN P06241 1/20 0.49
ADORA3 P0DMS8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118353 1.00 PTPN1 (0.68) PTPN1SLC7A5PTGS1ALPIPKM
SCHEMBL1258519 1.00 PTPN1 (0.68) PTPN1SLC7A5PTGS1ALPIPKM
Hydrochloric Acid SCHEMBL2309162 0.98 PTPN1 (0.67) PTPN1SLC7A5PTGS1ALPIPKM
SCHEMBL17658724 0.89 PTPN1 (0.54) PTPN1SLC7A5PTGS1ALPIPKM
SCHEMBL14945062 0.88 PTPN1 (0.74) PTPN1SLC7A5PTGS1ALPIPKM
SCHEMBL4946473 0.87 PTPN1 (0.52) PTPN1SLC7A5PTGS1ALPIPKM
SCHEMBL4946470 0.87 PTPN1 (0.52) PTPN1SLC7A5PTGS1ALPIPKM
SCHEMBL16080173 0.84 ACACB (0.50) PTPN1SLC7A5PTGS1ALPIPKM
SCHEMBL2058886 0.84 ACACB (0.53) PTPN1ITGB3ITGA2BACACBPTGS2
SCHEMBL2311151 0.84 ACACB (0.50) PTPN1SLC7A5PTGS1ALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120058841-A Synthesis method of snake venom tetrapeptide 上海鲲诺生物科技有限公司 2025-05-30 CN claimed
EP-3650464-B1 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND SHANGPHARMA INNOVATION INC (US) 2025-11-05 EP disclosed
CN-120058841-A Synthesis method of snake venom tetrapeptide 上海鲲诺生物科技有限公司 2025-05-30 CN disclosed
US-20250171494-A1 METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-05-29 US disclosed
CN-119930814-A D-peptide compounds directed against VEGF 反射制药有限公司 2025-05-06 CN disclosed
EP-4545553-A2 PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND ShangPharma Innovation Inc. (US) 2025-04-30 EP disclosed
US-12281141-B2 Method for synthesizing peptide containing N-substituted amino acid CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-04-22 US disclosed
EP-3647319-B1 PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME XDCEXPLORER SHANGHAI CO LTD (CN) 2025-04-09 EP disclosed
US-12129312-B2 Peptide compound, application thereof and composition containing same XDCEXPLORER (SHANGHAI) CO., LTD. (CN) 2024-10-29 US disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
EP-1487493-A2 CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES The Administrators of The Tulane Educational Fund (US) 2004-12-22 EP disclosed
US-6723699-B1 ADMINISTERING AS CHOLINERGIC AGENT TO TREAT NERVOUS SYSTEM DISORDERS CEPHALON, INC. 2004-04-20 US disclosed
US-6693076-B1 ENHANCING SURVIVAL OF NEURONAL CELLS AT RISK OF DYING DUE TO INJURY OR EPILEPSY CEPHALON, INC. 2004-02-17 US disclosed
WO-2003074551-A2 CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2003-09-12 WO disclosed
US-5580953-A USEFUL IN THERAPY OF TYPE 2 DIABETES MELLITUS, IMPAIRED GLUCOSE TOLERANCE, OBESITY AND INSULIN RESISTANCE AMYLIN PHARMACEUTICALS, INC. (US) 1996-12-03 US disclosed
EP-0568687-A1 NOVEL AMYLIN ANTAGONIST PEPTIDES AND USES THEREFOR AMYLIN PHARMACEUTICALS, INC. (US) 1993-11-10 EP disclosed
EP-0495963-A4 IMPROVED HYPOGLYCEMICS 1993-09-01 EP disclosed
WO-1993010147-A1 NOVEL AMYLIN ANTAGONIST PEPTIDES AND USES THEREFOR AMYLIN PHARMACEUTICALS, INC. (US) 1993-05-27 WO disclosed
EP-0495963-A1 IMPROVED HYPOGLYCEMICS AMYLIN PHARMACEUTICALS, INC. (US) 1992-07-29 EP disclosed
WO-1992003148-A1 IMPROVED HYPOGLYCEMICS AMYLIN CORPORATION (US) 1992-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129312-B2 Peptide compound, application thereof and composition containing same VIP, NGLY1, FURIN PTPN1 765/4885SLC7A5 395/4885PTGS1 4110/4885
US-20250171494-A1 METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID NPPA, VIP, DNPEP PTPN1 4356/4885SLC7A5 61/4885PTGS1 3389/4885
US-12281141-B2 Method for synthesizing peptide containing N-substituted amino acid NPPA, VIP, DNPEP PTPN1 4356/4885SLC7A5 61/4885PTGS1 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.